High-dose chemotherapy for rhabdomyosarcoma: where do we go from here

J Pediatr Hematol Oncol. 2001 Jun-Jul;23(5):266-7. doi: 10.1097/00043426-200106000-00005.

Authors

C L Mackall¹, L J Helman

Affiliation

¹ Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.

PMID: 11464979
DOI: 10.1097/00043426-200106000-00005

No abstract available

Publication types

Comment

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Bone Marrow Diseases / chemically induced
Bone Marrow Diseases / therapy
Child
Forecasting
Hematopoietic Stem Cell Transplantation
Humans
Multicenter Studies as Topic
Pilot Projects
Randomized Controlled Trials as Topic
Rhabdomyosarcoma / drug therapy*
Rhabdomyosarcoma / mortality
Soft Tissue Neoplasms / drug therapy*
Soft Tissue Neoplasms / mortality
Survival Rate
Treatment Outcome